{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T20:10:11Z","timestamp":1784578211972,"version":"3.55.0"},"reference-count":167,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"DST-PURSE"},{"name":"DRS-1"},{"DOI":"10.13039\/501100001501","name":"UGC, New Delhi, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.ejmech.2019.04.062","type":"journal-article","created":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T13:05:00Z","timestamp":1556715900000},"page":"269-286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"special_numbering":"C","title":["Development and future prospects of selective organometallic compounds as anticancer drug candidates exhibiting novel modes of action"],"prefix":"10.1016","volume":"175","author":[{"given":"Sabiha","family":"Parveen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farukh","family":"Arjmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5301-898X","authenticated-orcid":false,"given":"Sartaj","family":"Tabassum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2019.04.062_bib1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1039\/B707077M","article-title":"Bioorganometallic chemistry - from teaching paradigms to medicinal applications","volume":"38","author":"Hartinger","year":"2009","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2019.04.062_bib2","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.ccr.2006.11.017","article-title":"Using coordination chemistry to design new medicines","volume":"251","author":"Ronconi","year":"2007","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.ejmech.2019.04.062_bib3","doi-asserted-by":"crossref","first-page":"10793","DOI":"10.1039\/c1dt11007a","article-title":"Targeted and multifunctional arene ruthenium chemotherapeutics","volume":"40","author":"Smith","year":"2011","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2019.04.062_bib4","doi-asserted-by":"crossref","first-page":"7588","DOI":"10.1039\/b905798f","article-title":"A\u00a0categorization of metal anticancer compounds based on their mode of action","volume":"0","author":"Gianferrara","year":"2009","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2019.04.062_bib5","series-title":"Bioorganometallics: Biomolecules, Labeling, Medicine","first-page":"65","author":"Jaouen","year":"2006"},{"key":"10.1016\/j.ejmech.2019.04.062_bib6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cbpa.2012.01.013","article-title":"The potential of organometallic complexes in medicinal chemistry","volume":"16","author":"Gasser","year":"2012","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2019.04.062_bib7","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/(SICI)1521-3773(19980420)37:7<894::AID-ANIE894>3.0.CO;2-L","article-title":"Ligand design for electrochemically controlling stoichiometric and catalytic reactivity of transition metals","volume":"37","author":"Allgeier","year":"1998","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2019.04.062_bib8","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1039\/c2cc30678f","article-title":"Designing organometallic compounds for catalysis and therapy","volume":"48","author":"Noffke","year":"2012","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2019.04.062_bib9","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2174\/187152009789124646","article-title":"Titanium and vanadium complexes as anticancer agents","volume":"9","author":"Kostova","year":"2009","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib10","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/BF01047337","article-title":"Different inhibition pattern of the nucleic acid metabolism after in\u00a0vitro treatment with titanocene and vanadocene dichlorides","volume":"68","author":"Maier","year":"1981","journal-title":"Naturwissenschaften"},{"key":"10.1016\/j.ejmech.2019.04.062_bib11","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/BF00405494","article-title":"Tumor inhibition by titanocene dichloride: first clues to the mechanism of action","volume":"67","author":"Maier","year":"1980","journal-title":"Naturwissenschaften"},{"key":"10.1016\/j.ejmech.2019.04.062_bib12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0009-2797(83)90059-5","article-title":"Tumor inhibition by metallocenes: ultrastructural localization of titanium and vanadium in treated tumor cells by electron energy loss spectroscopy","volume":"44","author":"Maier","year":"1983","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2019.04.062_bib13","first-page":"273","article-title":"Intracellular distribution of titanium after treatment with the antitumor agent titanocene dichloride: on electron energy loss spectroscopic study","volume":"68","author":"Maier","year":"1981","journal-title":"Naturwissenschaften"},{"key":"10.1016\/j.ejmech.2019.04.062_bib14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jorganchem.2013.07.039","article-title":"Water-soluble arene ruthenium complexes, from serendipity to catalysis and drug design","volume":"751","author":"S\u00fcss-Fink","year":"2014","journal-title":"J.\u00a0Organomet. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib15","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.1021\/acs.jmedchem.7b01689","article-title":"Ru(II) compounds: next-generation anticancer metallotherapeutics?","volume":"61","author":"Thota","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib16","doi-asserted-by":"crossref","first-page":"212","DOI":"10.2174\/1871520616666160404110953","article-title":"Differential cytotoxicity, cellular uptake, apoptosis and inhibition of BRCA1 expression of BRCA1 -defective and sporadic breast cancer cells induced by an anticancer ruthenium(II)-Arene compound, RAPTA-EA1","volume":"17","author":"Ratanaphan","year":"2017","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib17","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/cbdv.200900288","article-title":"In\u00a0vitro ruthenation of human breast cancer suppressor gene 1 (BRCA1) by the antimetastasis compound RAPTA-C and its analogue carboRAPTA-C","volume":"7","author":"Ratanaphan","year":"2010","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.ejmech.2019.04.062_bib18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00775-010-0718-y","article-title":"Substitution of aspartic acid with glutamic acid at position 67 of BRCA1 RING domain retains ubiquitin ligase activity and zinc(II)-binding with a reduced transition temperature","volume":"16","author":"Atipairin","year":"2011","journal-title":"J.\u00a0Biol. Inorg. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib19","doi-asserted-by":"crossref","first-page":"13183","DOI":"10.3390\/ijms131013183","article-title":"Altered DNA binding and amplification of human breast cancer suppressor gene BRCA1 induced by a novel antitumor compound, [Ru(\u03b76-pphenylethacrynate)Cl2(pta)]","volume":"13","author":"Chakree","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2019.04.062_bib20","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jorganchem.2010.11.009","article-title":"Organometallic ruthenium-based antitumor compounds with novel modes of action","volume":"695","author":"Ang","year":"2011","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib21","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1038\/ncomms4462","article-title":"Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity","volume":"5","author":"Adhireksan","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2019.04.062_bib22","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1039\/C4SC03905J","article-title":"Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action","volume":"6","author":"Babak","year":"2015","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2019.04.062_bib23","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.2174\/1568026043387421","article-title":"Ruthenium antimetastatic agents","volume":"4","author":"Alessio","year":"2004","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib24","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/cmdc.201500478","article-title":"Fighting cancer with transition metal complexes: from naked DNA to protein and chromatin targeting strategies","volume":"11","author":"Palermo","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2019.04.062_bib25","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1039\/b904071d","article-title":"Recent developments in ruthenium anticancer drugs","volume":"1","author":"Levina","year":"2009","journal-title":"Metallomics"},{"key":"10.1016\/j.ejmech.2019.04.062_bib26","doi-asserted-by":"crossref","first-page":"9006","DOI":"10.1021\/ic061008y","article-title":"Development of organometallic Ruthenium\u2212Arene anticancer drugs that resist hydrolysis","volume":"45","author":"Ang","year":"2006","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1039\/B712656P","article-title":"Antitumour metal compounds: more than theme and variations","volume":"0","author":"Jakupec","year":"2008","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2019.04.062_bib28","doi-asserted-by":"crossref","first-page":"9069","DOI":"10.1039\/c1dt10522a","article-title":"Metal-based antitumour drugs in the post-genomic era: what comes next?","volume":"40","author":"Sava","year":"2011","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2019.04.062_bib29","doi-asserted-by":"crossref","first-page":"18269","DOI":"10.1073\/pnas.0505798102","article-title":"Controlling ligand substitution reactions of organometallic complexes: tuning cancer cell cytotoxicity","volume":"102","author":"Wang","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2019.04.062_bib30","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1039\/b601840h","article-title":"Metal-based antitumour drugs in the post genomic era","volume":"16","author":"Dyson","year":"2006","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2019.04.062_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/aoc.725","article-title":"Development of organometallic (organo-transition metal) pharmaceuticals","volume":"19","author":"Allardyce","year":"2005","journal-title":"Appl. Organomet. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/jm100020w","article-title":"Organometallic anticancer compounds","volume":"54","author":"Gasser","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib33","first-page":"20","volume":"vol. 30","author":"Hillard","year":"2011"},{"key":"10.1016\/j.ejmech.2019.04.062_bib34","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1021\/acs.organomet.8b00153","article-title":"(Pyridin-2-yl)-NHC organoruthenium complexes: antiproliferative properties and reactivity toward biomolecules","volume":"37","author":"Movassaghi","year":"2018","journal-title":"Organometallics"},{"key":"10.1016\/j.ejmech.2019.04.062_bib35","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1021\/om0300777","article-title":"Bioorganometallic Chemistry:\u2009 structural diversity of organometallic complexes with bioligands and molecular recognition studies of several supramolecular hosts with biomolecules, alkali-metal ions, and organometallic pharmaceuticals","volume":"22","author":"Fish","year":"2003","journal-title":"Organometallics"},{"key":"10.1016\/j.ejmech.2019.04.062_bib36","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.2174\/092986710791859306","article-title":"Organometallic complexes: new tools for chemotherapy","volume":"17","author":"Chavain","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib37","doi-asserted-by":"crossref","first-page":"10793","DOI":"10.1039\/c1dt11007a","article-title":"Targeted and multifunctional arene ruthenium chemotherapeutics","volume":"40","author":"Smith","year":"2011","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2019.04.062_bib38","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1039\/C8RA07926A","article-title":"Scope of organometallic compounds based on transition metal-arene systems as anticancer agents: starting from the classical paradigm to targeting multiple strategies","volume":"9","author":"Zaki","year":"2019","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2019.04.062_bib39","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1089\/ars.2010.3663","article-title":"Anticancer activity of metal complexes: involvement of redox processes","volume":"15","author":"Jungwirth","year":"2011","journal-title":"Antioxidants Redox Signal."},{"key":"10.1016\/j.ejmech.2019.04.062_bib40","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jorganchem.2017.03.038","article-title":"Advances in the design of organometallic anticancer complexes","volume":"839","author":"Zhang","year":"2017","journal-title":"J.\u00a0Organomet. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib41","doi-asserted-by":"crossref","first-page":"6582","DOI":"10.1038\/ncomms7582","article-title":"Transfer hydrogenation catalysis in cells as a new approach to anticancer drug design","volume":"6","author":"Soldevila-Barreda","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2019.04.062_bib42","first-page":"3","article-title":"Studies on DNA damage and induction of SOS repair by novel multifunctional bioreducible compounds. II. A metronidazole adduct of a ruthenium-arene compound","volume":"7","author":"Dale","year":"1992","journal-title":"Anti Cancer Drug Des."},{"key":"10.1016\/j.ejmech.2019.04.062_bib43","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2174\/092986706776360941","article-title":"Ruthenium complexes as anticancer agents","volume":"13","author":"Kostova","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib44","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ccr.2015.10.007","article-title":"Thiolato-bridged dinuclear arene ruthenium complexes and their potential as anticancer drugs","volume":"309","author":"Furrera","year":"2016","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.ejmech.2019.04.062_bib45","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.2174\/1568026043387421","article-title":"Ruthenium antimetastatic agents","volume":"4","author":"Alessio","year":"2004","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib46","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1002\/cbdv.200890195","article-title":"KP1019, a new redox-active anticancer agent \u2013 preclinical development and results of a clinical phase I study in tumor patients","volume":"5","author":"Hartinger","year":"2008","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.ejmech.2019.04.062_bib47","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1039\/B916860P","article-title":"Arene ruthenium complexes as anticancer agents","volume":"39","author":"Suess-Fink","year":"2010","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2019.04.062_bib48","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1039\/C3SC53243G","article-title":"NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application","volume":"5","author":"Trondl","year":"2014","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2019.04.062_bib49","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0022-328X(00)85370-X","article-title":"Ruthene (II) complexes with bidentate cycloheptatriene and benzene","volume":"7","author":"Winkhaus","year":"1967","journal-title":"J.\u00a0Organomet. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib50","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0022-328X(00)82927-7","article-title":"Reactions of \u03c0-benzeneruthenium (II) complexes with alkylating reagent","volume":"44","author":"Zelonka","year":"1972","journal-title":"J.\u00a0Organomet. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib51","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1139\/v72-486","article-title":"Benzene complexes of ruthenium (II)","volume":"50","author":"Zelonka","year":"1972","journal-title":"Can. J. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib52a","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2533\/chimia.2007.704","article-title":"The design of organometallic ruthenium arene anticancer agents","volume":"61","author":"Dougan","year":"2007","journal-title":"Chimia"},{"key":"10.1016\/j.ejmech.2019.04.062_bib52b","doi-asserted-by":"crossref","first-page":"18269","DOI":"10.1073\/pnas.0505798102","article-title":"Controlling ligand substitution reactions of organometallic complexes: tuning cancer cell cytotoxicity","volume":"102","author":"Deeth","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2019.04.062_bib53","doi-asserted-by":"crossref","first-page":"698","DOI":"10.2533\/chimia.2007.698","article-title":"Systematic design of a targeted organometallic antitumour drug in pre-clinical development","volume":"61","author":"Dyson","year":"2007","journal-title":"Chimia"},{"key":"10.1016\/j.ejmech.2019.04.062_bib54","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1039\/b104021a","article-title":"[Ru (\u03b76-p-cymene) Cl2 (pta)](pta= 1, 3, 5-triaza-7-phosphatricyclo-[3.3.1.1] decane): a water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells","author":"Allardyce","year":"2001","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2019.04.062_bib55","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1021\/jm010051m","article-title":"Inhibition of cancer cell growth by ruthenium (II) arene complexes","volume":"44","author":"Morris","year":"2001","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib56","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ccr.2015.06.014","article-title":"The development of RAPTA compounds for the treatment of tumors","volume":"306","author":"Murray","year":"2016","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.ejmech.2019.04.062_bib57","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1021\/jm060596m","article-title":"Structure\u2212 activity relationships for cytotoxic ruthenium (II) arene complexes containing N, N-, N, O-, and O, O-chelating ligands","volume":"49","author":"Habtemariam","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib58","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jinorgbio.2009.10.005","article-title":"In\u00a0vivo tumour and metastasis reduction and in\u00a0vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model","volume":"104","author":"Bergamo","year":"2010","journal-title":"J.\u00a0Inorg. Biochem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib59","doi-asserted-by":"crossref","first-page":"11544","DOI":"10.1021\/bi034933u","article-title":"DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media","volume":"42","author":"Novakova","year":"2003","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2019.04.062_bib60","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1002\/chem.200600110","article-title":"Ruthenation of duplex and single-stranded d(CGGCCG) by organometallic anticancer complexes","volume":"12","author":"Liu","year":"2006","journal-title":"Chem. Eur J."},{"key":"10.1016\/j.ejmech.2019.04.062_bib61","doi-asserted-by":"crossref","first-page":"17734","DOI":"10.1021\/ja053387k","article-title":"Competition between glutathione and guanine for a ruthenium(II) arene anticancer complex: detection of a sulfenato intermediate","volume":"127","author":"Wang","year":"2005","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2019.04.062_bib62","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/sj.bjc.6600290","article-title":"In\u00a0vitro and in\u00a0vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer","volume":"86","author":"Aird","year":"2002","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.ejmech.2019.04.062_bib63","series-title":"Topics in Organometallic Chemistry","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-3-642-13185-1_3","article-title":"Organometallic antitumour agents with alternative mode of action, Medicinal Inorganic Chemistry","volume":"vol. 32","author":"Casini","year":"2010"},{"key":"10.1016\/j.ejmech.2019.04.062_bib64","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0009-8981(99)00224-7","article-title":"Unraveling the role of proteases in cancer","volume":"291","author":"Koblinski","year":"2000","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ejmech.2019.04.062_bib65","first-page":"6010","article-title":"Inhibitory effects of antisense cathepsin B cDNA transfection on invasion and motility in a human osteosarcoma cell line","volume":"59","author":"Krueger","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2019.04.062_bib66","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/1097-0215(20010120)95:1<51::AID-IJC1009>3.0.CO;2-J","article-title":"Expression of cathepsins B and S in the progression of prostate carcinoma","volume":"95","author":"Fernandez","year":"2001","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2019.04.062_bib67","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.1038\/sj.onc.1204480","article-title":"Down-regulation of cathepsin B expression impairs the invasive and tumorigenic potential of human glioblastoma cells","volume":"20","author":"Mohanam","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2019.04.062_bib68","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1042\/bss0700263","article-title":"Cathepsin B and its role in cancer progression","volume":"70","author":"Podgorski","year":"2003","journal-title":"Biochem. Soc. Symp."},{"key":"10.1016\/j.ejmech.2019.04.062_bib69","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.2174\/092986706777935122","article-title":"Inhibitors of cathepsin B","volume":"13","author":"Frlan","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib70","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1039\/C1CC14713G","article-title":"Maleimide-functionalisedorganoruthenium anticancer agents and their binding to thiol-containing biomolecules","volume":"48","author":"Hanif","year":"2012","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2019.04.062_bib71","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1039\/C6SC00268D","article-title":"Structural tuning of organoruthenium compounds allows oxidative switch to control ER stress pathways and bypass multidrug resistance","volume":"7","author":"Chow","year":"2016","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2019.04.062_bib72","doi-asserted-by":"crossref","first-page":"13100","DOI":"10.1039\/C5DT01430A","article-title":"Dual-targeting organometallic ruthenium(II) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands","volume":"44","author":"Zhang","year":"2015","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2019.04.062_bib73","doi-asserted-by":"crossref","first-page":"10224","DOI":"10.1039\/c3cc43000f","article-title":"Complexation with organometallic ruthenium pharmacophoresenhances the ability of 4-anilinoquinazolines inducing apoptosis","volume":"49","author":"Zheng","year":"2013","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2019.04.062_bib74","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/aoc.864","volume":"19","author":"Rehmann","year":"2005","journal-title":"Appl. Organomet. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib75","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1021\/om301223k","article-title":"A\u00a0chloro-bridged heterobimetallic (\u03b76-Arene)ruthenium\u2013Organotin complex as an efficient topoisomerase I\u03b1 inhibitor","volume":"32","author":"Khan","year":"2013","journal-title":"Organometallics"},{"key":"10.1016\/j.ejmech.2019.04.062_bib76","doi-asserted-by":"crossref","first-page":"6667","DOI":"10.1039\/C5DT04400F","article-title":"Antitumor and biological investigation of doubly cyclometalated ruthenium(II) organometallics derived from benzimidazolyl derivatives","volume":"45","author":"Elumalai","year":"2016","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2019.04.062_bib77","series-title":"Metal Compounds in Cancer Therapy","first-page":"109","author":"Maier","year":"1994"},{"key":"10.1016\/j.ejmech.2019.04.062_bib78","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1358\/dof.1988.013.07.66340","article-title":"Antitumor-active bis-\u03b2-diketonato metal complexes: budotitane-a new anticancer agent","volume":"13","author":"Keppler","year":"1988","journal-title":"Drugs Future"},{"key":"10.1016\/j.ejmech.2019.04.062_bib79","series-title":"Metal Complexes in Cancer Chemotherapy","first-page":"187","author":"Keppler","year":"1993"},{"key":"10.1016\/j.ejmech.2019.04.062_bib80","first-page":"2701","article-title":"Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors","volume":"4","author":"Korfel","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2019.04.062_bib81","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.1998.16.8.2761","article-title":"Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer","volume":"16","author":"Christodoulou","year":"1998","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejmech.2019.04.062_bib82","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/1047-8477(90)90096-U","article-title":"Intracellular localization of titanium within xenografted sensitive human tumors after treatment with the antitumor agent titanocene dichloride","volume":"105","author":"Maier","year":"1990","journal-title":"J.\u00a0Struct. Biol."},{"key":"10.1016\/j.ejmech.2019.04.062_bib83","series-title":"Metal Compounds in Cancer Therapy","first-page":"109","article-title":"Organometallic titanium, vanadium, niobium, molybdenum and rhenium complexes \u2013 early transition metal antitumor drugs","author":"Maier","year":"1994"},{"key":"10.1016\/j.ejmech.2019.04.062_bib84","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1038\/bjc.1998.352","article-title":"Antiproliferative activity and mechanism of action of titanocene dichloride","volume":"77","author":"Christodoulou","year":"1998","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.ejmech.2019.04.062_bib85","first-page":"53","article-title":"Metallocene interactions with DNA and DNA-processing enzymes","volume":"33","author":"Kuo","year":"1996","journal-title":"Met. Ions Biol. Syst."},{"key":"10.1016\/j.ejmech.2019.04.062_bib86","series-title":"In\u00a0Vitro Treatment with Metallocene Dichlorides: Determination of the Intracellular Distribution of the Metal Atoms by Use of the Electron Energy Loss Spectroscopy, Cult Tech","first-page":"509","author":"Maier","year":"1981"},{"key":"10.1016\/j.ejmech.2019.04.062_bib87","first-page":"213","article-title":"Subcellular distribution of titanium in the liver after treatment with the antitumor agent titanocene dichloride. A study using electron spectroscopic imaging","volume":"57","author":"Maier","year":"1989","journal-title":"Cell Pathol. Inc. Mol. Pathol."},{"key":"10.1016\/j.ejmech.2019.04.062_bib88","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0009-2797(83)90059-5","article-title":"Tumor inhibition by metallocenes: ultrastructural localization of titanium and vanadium in treated tumor cells by electron energy loss spectroscopy","volume":"44","author":"Maier","year":"1983","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2019.04.062_bib89","doi-asserted-by":"crossref","first-page":"8949","DOI":"10.1021\/ja00180a046","article-title":"DNA-metal binding by antitumor-active metallocene dichlorides from inductively coupled plasma spectroscopy analysis: titanocene dichloride forms DNA-Cp2Ti or DNA-CpTi adducts depending on pH","volume":"112","author":"McLaughlin","year":"1990","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2019.04.062_bib90a","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1021\/ic101693v","article-title":"Different ortho and para Electronic Effects on Hydrolysis and Cytotoxicity of Diamino Bis(Phenolato) \u201cSalan\u201d Ti(IV) Complexes","volume":"50","author":"Peri","year":"2011","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib90b","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.1039\/b708283p","article-title":"Functionalised cyclopentadienyl titanium compounds as potential anticancer drugs","volume":"0","author":"Allen","year":"2007","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2019.04.062_bib90c","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.inoche.2006.07.019","article-title":"Cellular toxicities of new titanocene dichloride derivatives containing pendant cyclic alkylammonium groups","volume":"9","author":"Potter","year":"2006","journal-title":"Inorg. Chem. Commun."},{"key":"10.1016\/j.ejmech.2019.04.062_bib91","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/(SICI)1521-3773(19980619)37:11<1577::AID-ANIE1577>3.0.CO;2-M","article-title":"The first specific TiIV-protein complex: potential relevance to anticancer activity of titanocenes","volume":"37","author":"Sun","year":"1998","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2019.04.062_bib92","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/aoc.864","volume":"19","author":"Rehmann","year":"2005","journal-title":"Appl. Organomet. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib93","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1016\/j.ica.2006.05.021","article-title":"Diheteroarylmethyl substituted titanocenes: a novel class of possible anti-cancer drugs","volume":"359","author":"Pampillon","year":"2006","journal-title":"Inorg. Chim. Acta"},{"key":"10.1016\/j.ejmech.2019.04.062_bib94","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/j.jorganchem.2007.01.045","article-title":"Synthesis and cytotoxicity studies of new dimethylamino-functionalised and heteroaryl-substituted titanocene anti-cancer drugs","volume":"692","author":"Pampillon","year":"2007","journal-title":"J.\u00a0Organomet. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib95","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1016\/j.jorganchem.2004.04.015","article-title":"Novel titanocene anti-cancer drugs derived from fulvenes and titanium dichloride","volume":"689","author":"Tacke","year":"2004","journal-title":"J.\u00a0Organomet. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2004.09.001","article-title":"Methoxy-phenyl substituted ansa-titanocenes as potential anti-cancer drugs derived from fulvenes and titanium dichloride","volume":"98","author":"Tacke","year":"2004","journal-title":"J.\u00a0Inorg. Biochem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib97","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s10495-006-6796-1","article-title":"Novel titanocene anti-cancer drugs and their effect on apoptosis and the apoptotic pathway in prostate cancer cells","volume":"11","author":"O'Connor","year":"2006","journal-title":"Apoptosis"},{"key":"10.1016\/j.ejmech.2019.04.062_bib98a","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.theochem.2009.10.007","article-title":"The hydrolysis chemistry of anticancer drug titanocene dichloride: an insight from theoretical study","volume":"940","author":"Chen","year":"2010","journal-title":"J.\u00a0Mol. Struct."},{"key":"10.1016\/j.ejmech.2019.04.062_bib98b","first-page":"302","article-title":"Mechanisms of cytotoxicity of anticancer titanocenes, anti-cancer agents","volume":"10","author":"Olszewski","year":"2010","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib99","doi-asserted-by":"crossref","first-page":"9580","DOI":"10.1039\/c1dt10805k","article-title":"Pharmaceutical formulation affects titanocene transferrin interactions","volume":"40","author":"Buettner","year":"2011","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2019.04.062_bib100","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jinorgbio.2010.04.004","article-title":"Redox potentials of Ti(IV) and Fe(III) complexes provide insights into titanium biodistribution mechanisms","volume":"104","author":"Siburt","year":"2010","journal-title":"J.\u00a0Inorg. Biochem."},{"key":"10.1016\/j.ejmech.2019.04.062_sref98","unstructured":"J."},{"key":"10.1016\/j.ejmech.2019.04.062_bib101a","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1021\/om500965k","article-title":"Organometallic titanocene\u2013gold compounds as potential chemotherapeutics in renal cancer. Study of their protein kinase inhibitory properties","volume":"33","author":"Gallardo","year":"2014","journal-title":"Organometallics"},{"key":"10.1016\/j.ejmech.2019.04.062_bib101b","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1021\/acs.organomet.6b00051","article-title":"Titanocene\u2212Gold complexes containing N-heterocyclic carbene ligands inhibit growth of prostate, renal, and colon cancers in\u00a0vitro","volume":"35","author":"Mui","year":"2016","journal-title":"Organometallics"},{"key":"10.1016\/j.ejmech.2019.04.062_bib102","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1039\/a908759a","article-title":"Competitive binding of the anticancer drug titanocene dichloride to N,N[hair space]\u2032-ethylenebis(o-hydroxyphenylglycine) and adenosine triphosphate: a model for TiIV uptake and release by transferrin","volume":"0","author":"Guo","year":"2000","journal-title":"J.\u00a0Chem. Soc. Dalton Trans."},{"key":"10.1016\/j.ejmech.2019.04.062_bib103","doi-asserted-by":"crossref","first-page":"10023","DOI":"10.1021\/bi000798z","article-title":"TiIV uptake and release by human serum transferrin and recognition of TiIV-transferrin by cancer Cells:\u2009 understanding the mechanism of action of the anticancer drug titanocene dichloride","volume":"39","author":"Guo","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2019.04.062_bib104","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s007750100248","article-title":"Titanium(IV) targets phosphoesters on nucleotides: implications for the mechanism of action of the anticancer drug titanocene dichloride","volume":"6","author":"Guo","year":"2001","journal-title":"J.\u00a0Biol. Inorg. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib105","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1002\/anie.200600260","article-title":"Short oxo\u2013titanium(IV) bond in bacterial transferrin: a protein target for metalloantibiotics","volume":"45","author":"Guo","year":"2006","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2019.04.062_bib106","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1039\/C6CS00860G","article-title":"Using titanium complexes to defeat cancer: the view from the shoulders of titans","volume":"46","author":"Cini","year":"2017","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2019.04.062_bib107","first-page":"21","article-title":"Activation mechanisms for organometallic anticancer complexes","volume":"32","author":"Pizarro","year":"2010","journal-title":"Med. Organomet. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib108","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1040-8428(01)00216-5","article-title":"Gold derivatives for the treatment of cancer","volume":"42","author":"Tiekink","year":"2002","journal-title":"Crit. Rev. Oncol.Hematol."},{"key":"10.1016\/j.ejmech.2019.04.062_bib109","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.ccr.2009.02.026","article-title":"Thioredoxin reductase: a target for gold compounds acting as potential anticancer drugs","volume":"253","author":"Bindoli","year":"2009","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.ejmech.2019.04.062_bib110","doi-asserted-by":"crossref","first-page":"8786","DOI":"10.1039\/C5CS00132C","article-title":"Chemical biology of anticancer gold(III) and gold(I) complexes","volume":"44","author":"Zou","year":"2015","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2019.04.062_bib111","series-title":"Chemistry and Biochemistry of Flavoenzymes","first-page":"121","article-title":"Lipoamide dehydrogenase, glutathione reductase, thioredoxin reductase, and mercuric ion reductase\u2014a family of flavoenzyme transhydrogenases","author":"Williams","year":"1992"},{"key":"10.1016\/j.ejmech.2019.04.062_bib112","doi-asserted-by":"crossref","first-page":"6102","DOI":"10.1046\/j.1432-1327.2000.01701.x","article-title":"Physiological functions of thioredoxin and thioredoxin reductase","volume":"267","author":"Arn\u00e9r","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib113","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1089\/ars.2005.7.823","article-title":"Thioredoxin and its related molecules: update 2005","volume":"7","author":"Nakamura","year":"2005","journal-title":"Antioxidants Redox Signal."},{"key":"10.1016\/j.ejmech.2019.04.062_bib114","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.freeradbiomed.2005.04.025","article-title":"Inhibition of thioredoxi reductase but not of glutathione reductase by the major classes of alkylating and platinum containing anticancer compounds","volume":"39","author":"Witte","year":"2005","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejmech.2019.04.062_bib115","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.ccr.2007.04.006","article-title":"Targeting the mitochondrial cell death pathway with gold compounds","volume":"251","author":"Barnard","year":"2007","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.ejmech.2019.04.062_bib116","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.jinorgbio.2004.04.020","article-title":"Gold complexes inhibit mitochondrial thioredoxin reductase: consequences on mitochondrial functions","volume":"98","author":"Rigobello","year":"2004","journal-title":"J.\u00a0Inorg. Biochem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib117","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.bcp.2003.09.038","article-title":"Mitochondrial thioredoxin reductase inhibition by gold(I) compounds and concurrent stimulation of permeability transition and release of cytochrome c","volume":"67","author":"Rigobello","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.04.062_bib118","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.tiv.2006.01.012","article-title":"Sublethal concentrations of diverse gold compounds inhibit mammalian cytosolic thioredoxin reductase (TrxR1)","volume":"20","author":"Omata","year":"2006","journal-title":"Toxicol. Vitro"},{"key":"10.1016\/j.ejmech.2019.04.062_bib119","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.bcp.2007.07.022","article-title":"A\u00a0gold(I) phosphine complex selectively induces apoptosis in breast cancer cells: implications for anticancer therapeutics targeted to mitochondria","volume":"74","author":"Rackham","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.04.062_bib120","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.ccr.2009.02.026","article-title":"A\u00a0target for gold compounds acting as potential anticancer drugs","volume":"253","author":"Bindoli","year":"2009","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.ejmech.2019.04.062_bib121","doi-asserted-by":"crossref","first-page":"20096","DOI":"10.1074\/jbc.273.32.20096","article-title":"Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds","volume":"273","author":"Gromer","year":"1998","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib122","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/00001813-200606000-00007","article-title":"Thioredoxin reductase and cancer cell growth inhibition by organogold(III) compounds","volume":"17","author":"Engman","year":"2006","journal-title":"Anti Canccer Drugs"},{"key":"10.1016\/j.ejmech.2019.04.062_bib123","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1039\/C5DT01802A","article-title":"In\u00a0vitro and in\u00a0vivo evaluation of organometallic gold(I) derivatives as anticancer agents","volume":"45","author":"Moreno","year":"2016","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2019.04.062_bib124","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1039\/C3DT52524D","article-title":"A\u00a0golden future in medicinal inorganic chemistry: the promise of anticancer gold organometallic compounds","volume":"43","author":"Bertranda","year":"2014","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2019.04.062_bib125","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1039\/b303294a","article-title":"Gold(III) porphyrins as a new class of anticancer drugs: cytotoxicity, DNA binding and induction of apoptosis in human cervix epitheloid cancer cells","volume":"0","author":"Che","year":"2003","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2019.04.062_bib126","doi-asserted-by":"crossref","first-page":"4364","DOI":"10.1039\/C2CC37366A","article-title":"A\u00a0gold(III) porphyrin complex as an anti-cancer candidate to inhibit growth of cancer-stem cells","volume":"49","author":"Lum","year":"2013","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2019.04.062_bib127","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cmdc.201402049","article-title":"Gold(I) N-heterocyclic carbene complexes with naphthalimide ligands as combined thioredoxin reductase inhibitors and DNA intercalators","volume":"8","author":"Meyer","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2019.04.062_bib128","doi-asserted-by":"crossref","first-page":"5810","DOI":"10.1002\/anie.201400142","article-title":"A\u00a0binuclear gold(I) complex with mixed bridging diphosphine and bis(N-heterocyclic carbene) ligands shows favorable thiol reactivity and inhibits tumor growth and angiogenesis in\u00a0vivo","volume":"53","author":"Zou","year":"2014","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2019.04.062_bib129","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1039\/C5NJ01449B","article-title":"Recent advances in iron complexes as potential anticancer agents","volume":"40","author":"Wani","year":"2016","journal-title":"New J. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib130","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.mam.2005.07.010","article-title":"Iron and copper metabolism","volume":"26","author":"Arredondo","year":"2005","journal-title":"Mol. Aspect. Med."},{"key":"10.1016\/j.ejmech.2019.04.062_bib131","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1146\/annurev.nutr.20.1.627","article-title":"Iron regulatory proteins and the molecular control of mammalian iron metabolism","volume":"20","author":"Eisenstein","year":"2000","journal-title":"Annu. Rev. Nutr."},{"key":"10.1016\/j.ejmech.2019.04.062_bib132","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1079\/PNS2004394","article-title":"Iron nutrition in the UK: getting the balance right","volume":"63","author":"Fairweather-Tait","year":"2004","journal-title":"Proc. Nutr. Soc."},{"key":"10.1016\/j.ejmech.2019.04.062_bib133","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/anie.198404561","article-title":"Ferrocenium salts-the first antineoplastic iron compounds","volume":"23","author":"Maier","year":"1984","journal-title":"Angew. Chem., Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2019.04.062_bib134","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1021\/cr00081a012","article-title":"Non-platinum-group metal antitumor agents: history, current status, and perspectives","volume":"89","author":"Maier","year":"1987","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2019.04.062_bib135","first-page":"103","volume":"vol. 70","author":"Maier","year":"1988"},{"key":"10.1016\/j.ejmech.2019.04.062_bib136","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/BF00390468","article-title":"Ferricenium complexes: a new type of water-soluble antitumor agent","volume":"108","author":"Maier","year":"1984","journal-title":"J.\u00a0Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2019.04.062_bib137","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0162-0134(00)00198-7","article-title":"Inhibition of human topoisomerase II by the antitumor metallocenes","volume":"83","author":"Mokdsi","year":"2001","journal-title":"J.\u00a0Inorg. Biochem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib138","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1006\/abbi.1999.1692","article-title":"Topoisomerase II poisoning and antineoplastic action by DNA-nonbinding diacetyl and dicarboxaldoxime of Ferrocene","volume":"376","author":"Gopal","year":"2000","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2019.04.062_bib139","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0020-1693(00)00147-X","article-title":"On the mechanism of the antitumor activity of ferrocenium derivatives","volume":"306","author":"Osella","year":"2000","journal-title":"Inorg. Chim. Acta"},{"key":"10.1016\/j.ejmech.2019.04.062_bib140","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1246\/cl.1997.1177","article-title":"DNA cleaving activity and cytotoxic activity of ferricenium cations","volume":"26","author":"Tamura","year":"1997","journal-title":"Chem. Lett."},{"key":"10.1016\/j.ejmech.2019.04.062_bib141","first-page":"205","article-title":"Anti-cancer action of metal complexes: electron transfer and oxidative stress?","volume":"3","author":"Kovavic","year":"1988","journal-title":"Anti Cancer Drug Des."},{"key":"10.1016\/j.ejmech.2019.04.062_bib142","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1023\/A:1016686321179","article-title":"A\u00a0new class of drugs for BNCT? Borylated derivatives of ferrocenium compounds in animal experiments","volume":"14","author":"Weissfloch","year":"2001","journal-title":"Biometals"},{"key":"10.1016\/j.ejmech.2019.04.062_bib143","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0022-328X(91)86350-Y","article-title":"Studies on the antitumor activity of some iron sandwich compounds","volume":"418","author":"Houlton","year":"1991","journal-title":"J.\u00a0Organomet. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib144","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0960-894X(00)80590-9","article-title":"A\u00a0ferrocene intercalator conjugate with a potent cytotoxicity","volume":"2","author":"Ong","year":"1992","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.04.062_bib145","first-page":"617","article-title":"Ferrocenes (F168, F169) and fero-sorbitol-citrate (FSC): potential anticancer drugs","volume":"15","author":"Vidovic","year":"2000","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.ejmech.2019.04.062_bib146","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0022-328X(90)85506-T","article-title":"Synthesis and acitivity of potential antitumor ferrocenes","volume":"398","author":"Motohashi","year":"1990","journal-title":"J.\u00a0Organomet. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib147","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/anie.200504604","article-title":"New principles in medicinal organometallic chemistry","volume":"45","author":"Schatzschneider","year":"2006","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2019.04.062_bib148","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2533\/chimia.2007.716","article-title":"Ferrocifens and ferrocifenols as new potential weapons against breast cancer","volume":"61","author":"Nguyen","year":"2007","journal-title":"Chimia"},{"key":"10.1016\/j.ejmech.2019.04.062_bib149","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.2174\/0929867043364487","article-title":"The first organometallic selective estrogen receptor modulators (SERMs) and their relevance to breast cancer","volume":"11","author":"Jaouen","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib150","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0022-328X(97)00086-7","article-title":"Facile route to ferrocifen, 1-[4-(2-dimethylaminoethoxy)]-1-(phenyl-2-ferrocenyl-but-1-ene), first organometallic analogue of tamoxifen, by the McMurry reaction","volume":"541","author":"Top","year":"1997","journal-title":"J.\u00a0Organomet. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib151","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1039\/CC9960000955","article-title":"Ferrocenyl hydroxytamoxifen: a prototype for a new range of oestradiol receptor site-directed cytotoxics","volume":"8","author":"Top","year":"1996","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2019.04.062_bib152","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ica.2012.06.007","article-title":"Metallocenes as target specific drugs for cancer treatment","volume":"393","author":"Mel\u00e9ndez","year":"2012","journal-title":"Inorg. Chim. Acta"},{"key":"10.1016\/j.ejmech.2019.04.062_bib153","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0022-328X(01)00953-6","article-title":"Studies on organometallic selective estrogen receptor modulators (SERMs) Dual activity in the hydroxy-ferrocifen series","volume":"637","author":"Top","year":"2001","journal-title":"J.\u00a0Organomet. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib154","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1002\/chem.200305024","volume":"9","author":"Top","year":"2003","journal-title":"Chem. Eur J."},{"key":"10.1016\/j.ejmech.2019.04.062_bib155","doi-asserted-by":"crossref","first-page":"8802","DOI":"10.1039\/C5CS00486A","article-title":"Ferrocifen type anti cancer drugs","volume":"44","author":"Jaouen","year":"2015","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2019.04.062_bib156","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/cmdc.201402219","article-title":"Molecular mechanism of action of 2-Ferrocenyl-1,1-diphenylbut-1-ene on HL-60 leukemia cells","volume":"9","author":"de Oliveira","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2019.04.062_bib157","doi-asserted-by":"crossref","first-page":"8849","DOI":"10.1021\/jm5013165","article-title":"Evidence for targeting thioredoxin reductases with ferrocenyl quinone methides. A possible molecular basis for the antiproliferative effect of hydroxyferrocifens on cancer cells","volume":"57","author":"Citta","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib158","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1021\/jm901866m","article-title":"Novel ferrocenic steroidal drug derivatives and their bioactivities","volume":"53","author":"Manosroi","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib159","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00432-010-0924-6","article-title":"Iron containing anti-tumoral agents: unexpected apoptosis-inducing activity of a ferrocene amino acid derivative","volume":"137","author":"Kater","year":"2011","journal-title":"J.\u00a0Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2019.04.062_bib160","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1021\/bc100158b","article-title":"New potential anticancer agent of carborane derivatives: selective cellular interaction and activity of ferrocene-substituted dithio-o-carborane conjugates","volume":"22","author":"Wu","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2019.04.062_bib161","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jinorgbio.2013.07.033","article-title":"Important cytotoxicity of novel iron(II) cyclopentadienyl complexes with imidazole based ligands","volume":"129","author":"Goncalves","year":"2013","journal-title":"J.\u00a0Inorg. Biochem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419303861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419303861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:54:45Z","timestamp":1759326885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523419303861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":167,"alternative-id":["S0223523419303861"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.04.062","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and future prospects of selective organometallic compounds as anticancer drug candidates exhibiting novel modes of action","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.04.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}